UNC Charlotte researchers are contributing to pioneering breakthroughs in cancer therapeutics, communicable disease ...

A gene therapy to correct a mutation that causes maple syrup urine disease prevented newborn death and normalized growth in a calf as well as in mice.

Sarepta Therapeutics hits 52-week lows despite strong earnings and growth. Read why investors should view SRPT as a high risk ...

Financially, Monopar has a cash runway until 2026 but will need additional funds for commercialization efforts. See why I'm ...

Bone density dramatically declines as we age, and is accelerated among those who don't perform resistance exercise or ...

The changes at Spark follow Roche's decision last year to halt development of a gene therapy for hemophilia A that was the ...

Faster Clinical Translation and Commercialization of Therapies Derived From iPSC Technology GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and ...

The Phase 3 ARTEMIS trial (NCT06856577) is designed to evaluate the safety and efficacy of Ixo-vec in a randomized (1:1), double-masked, sham-controlled, two-arm study. The US-based trial is intended ...

Welcome to the BioLife Solutions Q4 2024 shareholder and analyst conference call. (Operator Instructions). As a reminder, today's call is being recorded. I would now like to turn the conference call ...

Cash Position: As of December 31, 2024, Fractyl had approximately $67.5 million in cash and cash equivalents. Based on ...

Researchers at Fred Hutch Cancer Center have discovered an overlooked mechanism driving aggressive breast and brain tumors ...

BOTHELL, Wash. - BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading provider of cell processing tools for the cell and gene therapy market, saw its shares jump 7.9% after reporting ...